Sucampo Re-Embraces Amitiza Through Co-Promote Option After Rescula Falters
This article was originally published in The Pink Sheet Daily
Executive Summary
While the company had been hopeful about diversifying its revenue base with the launch of its glaucoma drug Rescula, those hopes have faltered and pushed Sucampo to try to maximize the potential behind its main sales-driver, the constipation treatment Amitiza.
You may also be interested in...
Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization
Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.